Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-29

Optimised and novel oncolytic adenoviruses and pox viruses in the treatment of cancer: Virotherapy combined with molecular chemotherapy

Objective

Cancer is today the second cause of disease-induced mortality worldwide. Among innovative treatments for cancer, virotherapy holds great promise. Virotherapy exploits an intrinsic feature of the lifecycle of oncolytic viruses (OVs): replication and spreading exclusively in tumour cells leading to their destruction, while not affecting normal cells.
Clinical studies have demonstrated the safety and feasibility of this approach, but have shown only minimal therapeutic efficacy. Synergistic effects of combination treatments of OVs with chemo- and radiation therapy have been observed. Nevertheless, this approach still leaves patients subjected to the toxic adverse effects of chemotherapy and radiation. Thus, an unmet need exists for the improvement of current and the development of new treatment platforms leading to a significant increase in cure rates.
Owing to their inherent strong oncolytic potency and safety record, pox virus and adenovirus based vectors have been chosen to pursue the goal of the THERADPOX project: to improve the safety and therapeutic efficacy of OVs in vivo. Novel and improved OVs will be engineered which, in vivo i) specifically target colorectal, pancreatic and ovarian cancer cells, ii) replicate exclusively in cancer cells, iii) are armed with therapeutic genes rendering only tumour cells sensitive to chemotherapy, and iv) widely spread within the tumour to permit total tumour eradication. Through the multidisciplinary workplan proposed and the strong and complementary expertise of the 10 European partners involved, the THERADPOX project will i) generate advanced knowledge which could be translated towards a safer cancer treatment with an increased therapeutic index, ii) contribute to improve the quality of life of cancer patients by fewer treatments with no toxic side effects, iii) lead to the proposal of new guidelines and standards for the development of OVs, and iv) strengthen the competitiveness of Europe.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP6-2004-LIFESCIHEALTH-5
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

STREP - Specific Targeted Research Project

Coordinator

TRANSGENE, S.A.
EU contribution
No data
Address
Boulevard Gonthier d'Andernach - Parc d'Innovation - CS80166
ILLKIRCH GRAFFENSTADEN
France

See on map

Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (9)

My booklet 0 0